Key takeaways
- A new meta-analysis in JAMA Psychiatry ranks semaglutide as the most effective medication for combating weight gain caused by antipsychotics.
- Semaglutide led to an average weight loss of 24.2 pounds, outperforming the historical standard treatment, metformin, by nearly threefold.
- Psychiatric patients face a significantly reduced life expectancy due to metabolic side effects, making effective weight management a critical medical need.
- Cash-pay telehealth buyers must balance the superior efficacy of semaglutide with the lower costs of oral options like metformin.
What happened
A comprehensive systematic review and network meta-analysis published in JAMA Psychiatry has revealed that GLP-1 receptor agonists—particularly semaglutide—are the most effective medications for reversing the severe weight gain associated with antipsychotic drugs. Led by Dr. Sri Mahavir Agarwal of the University of Toronto Centre for Addiction and Mental Health, researchers analyzed data from 95 clinical trials representing 39 different drug interventions and 5,898 participants. The study establishes a clear hierarchy of weight-loss options for psychiatric patients, showing that semaglutide outperforms traditional alternatives like metformin and topiramate by a wide margin.
Why it matters
Antipsychotic medications are life-saving treatments for schizophrenia spectrum disorders, but they carry a heavy metabolic toll. The resulting weight gain, insulin resistance, and cardiovascular issues contribute to a tragic reality: individuals with serious mental illness face a life expectancy that is 10 to 25 years shorter than the general population.
Previously, patients and mental health providers viewed rapid weight gain as an unavoidable trade-off for psychiatric stability. This side effect frequently leads to patients stopping their psychiatric medications, which triggers relapses. For US patients who manage their mental health through psychiatric providers and want to address metabolic health via telehealth, these findings provide clinical justification for adding a GLP-1 to their care regimen. It offers a path to protect metabolic health without sacrificing psychological stability.
What the data says
The meta-analysis evaluated the average body weight reductions compared to a placebo. Based on moderate-certainty clinical evidence, the drugs associated with the most significant weight loss were:
- Semaglutide ([Wegovy](/ozempic-vs-wegovy)): Lost an average of 10.98 kg (24.2 lbs)
- Liraglutide (Saxenda): Lost an average of 5.43 kg (12.0 lbs)
- Topiramate: Lost an average of 3.95 kg (8.7 lbs)
- Metformin: Lost an average of 3.86 kg (8.5 lbs)
- Exenatide (Byetta): Lost an average of 2.97 kg (6.5 lbs)
Of these options, only semaglutide and metformin achieved "clinically meaningful" weight loss, defined as losing at least 5% of total body weight. The analysis also noted positive improvements in secondary metabolic markers, including patient lipid profile and glucose levels.
In terms of safety and tolerability, GLP-1 medications did show slightly higher rates of mild-to-moderate gastrointestinal side effects, such as nausea, vomiting, diarrhea, and dyspepsia. However, patient dropout and drug discontinuation rates were not significantly higher than those seen in the placebo groups.
How it compares
For years, metformin was the clinical gold standard for countering antipsychotic-induced weight gain. It is highly accessible and cheap, with cash-pay prices typically under $15 per month. However, this new data shows that semaglutide is nearly three times more effective than metformin, yielding an average weight loss of 24.2 pounds compared to metformin's 8.5 pounds.
For cash-paying telehealth consumers in the US, choosing between these therapies comes down to a balance of clinical efficacy and budget:
- Brand-Name GLP-1s: Brand-name Wegovy (semaglutide) carries a list price of roughly $1,350 per month. Unless a patient has commercial insurance that covers obesity treatments, this cost is prohibitive for many.
- Compounded Semaglutide: Online clinical providers offer compounded semaglutide, which frequently contains the same active pharmaceutical ingredient. These telehealth services typically cost between $150 and $300 per month, including both the medical consultation and the shipped medication.
- Oral Metformin and Topiramate: Many budget-tier weight loss platforms prescribe generic oral metformin or topiramate for $20 to $50 per month. While far more affordable, the JAMA Psychiatry study proves these options are vastly less effective than semaglutide for reversing antipsychotic weight gain.
How this fits the bigger picture
This study marks a major milestone in expanding the clinical use cases for GLP-1 medications beyond standard weight loss and type 2 diabetes. We are seeing a steady flow of clinical trials proving these peptides treat complex systemic diseases. For example, recent data has linked GLP-1s to reduced relapse rates in multiple sclerosis patients, as covered in our report on GLP-1 drugs and MS relapse rates.
However, using GLP-1s alongside psychiatric medications requires specialized medical oversight. Some weight-loss peptides can interact with psychiatric drugs. A prime example is detailed in our coverage of tirzepatide and lithium toxicity risks, which highlights how delayed gastric emptying can alter the absorption and blood concentrations of psychiatric stabilizers.
What this likely means for US buyers is that standard "text-only" or low-cost automated GLP-1 subscription sites may not provide the comprehensive care psychiatric patients need. Because antipsychotics require careful monitoring, patients looking to add semaglutide should seek out telehealth platforms that feature comprehensive intake processes and direct access to licensed clinicians who can coordinate care with their primary psychiatrist.
What happens next
The researchers noted that because the clinical trial data lags behind drug developments, Eli Lilly's tirzepatide (Zepbound) was not included in this meta-analysis. Given that tirzepatide generally yields higher weight loss percentages than semaglutide in head-to-head clinical trials, future psychiatric studies will likely evaluate its efficacy in reversing antipsychotic weight gain.
In the meantime, these findings are expected to influence clinical guidelines. Mental health advocacy groups and psychiatric associations may begin recommending early intervention with GLP-1 receptor agonists alongside metabolic-heavy antipsychotic prescriptions, rather than waiting for severe cardiovascular complications to arise.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare professional or your psychiatrist before starting, stopping, or altering any medication regimen.

